Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Favipiravir is a viral RNA polymerase inhibitor that has been tested to treat influenza A and B viruses, Ebola, Lassa, and coronavirus 2019-nCoV (Joshi 2021, Shiraki 2020).
Oral administration twice a day for 5 days.
At the date of the last update, the authors did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight and low protein binding) make it likely to pass to milk in an amount that could be significant, although the moderately high volume of distribution and high pKa would make it difficult.
Its possible side effects are diarrhea, decreased neutrophils, and elevated transaminases and uric acid (Taisho 2014).
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.
See below the information of these related products: